Table 2. Overall survivals related to several clinicopathological characteristics with gastric cancer patients.

Variables	Patients	Events	Median survival, months (95% CI)	Log rank test
Gender
Male	184	78	38.0±6.5 (25.3-50.7)	0.400
Female	72	26	NA
Age, year
≤60	127	46	47.3	0.349
>60	129	48	36.0±5.1 (25.9-46.1)
Tumor site
(I) Upper	55	26	38.0±8.9 (20.6-55.4)	0.537
Middle	52	20	NA
Low	129	52	NA
(II) Cardiac cancer	49	26	26.5±4.8 (17.2-36.0)	0.029
Non-cardiac cancer	207	78	NA
Tumor size
≤4 cm	108	37	NA	0.062
>4 cm	100	52	31.1±3.1 (25.1-37.1)
Lauren
Intestinal	148	56	41.5±5.5 (30.8-52.2)	0.015
diffuse	78	39	28.0±8.1 (12.1-43.9)
mixed	24	7	NA
Differentiation
Well-Moderate	114	41	47.3	0.046
Poor	127	56	34.3
Histology
Adenocarcinoma	192	83	38.0±5.6 (26.9-49.1)	0.479
Other types	61	20	NA
Lymphovascular invasion
Absent	135	40	NA	0.000
Present	118	63	25.0±3.2 (18.6-31.4)
Depth of invasion
T1+T2+T3	139	45	NA	0.000
T4	114	59	28.0±2.8 (22.5-33.5)
Lymph node metastasis
N0	52	10	NA	0.002
N1+N2+N3	194	92	31.8±3.0 (25.9-37.7)
Distant metastasis
No	211	73	NA	0.000
Yes	36	30	12.0±1.5 (9.1-14.9)
TNM stage
I+II	89	12	NA	0.000
III+IV	158	91	25.0±3.3 (18.5-31.5)
LGR5
(I) Negative (-)	123	50	NA	0.872
Weak positive (+)	73	29	47.3±11.6 (24.5-70.1)
Moderate positive (++)	43	19	38.0±5.0 (28.3-47.7)
Strong positive (+++)	17	6	NA
(II) Negative	123	50	NA	0.891
Positive	133	54	38.0±4.0 (30.2-45.8)
(III) Low expression	196	79	47.3	0.947
High expression	60	25	38.0±4.5 (29.1-46.9)

NA, because the overall survival rates of these patients were more than 50%, we didn’t get the median survival time